# Avidity Partners

> Avidity Partners is a VC fund backing Biotechnology and Health Care. See 73 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 73
- Last investment: Apr 2026
- Lead investor: 16%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/avidity-partners/

Avidity Partners is an investment management firm that offers financial services.

## Contacts

5 contacts available for Avidity Partners. Shizune tracks 1 team members at Avidity Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/avidity-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 44 | 60% |
| Health Care | 39 | 53% |
| Pharmaceutical | 19 | 26% |
| Medical | 18 | 25% |
| Therapeutics | 17 | 23% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 29 | 40% |
| Series B | 16 | 22% |
| Series C | 10 | 14% |
| Series A | 3 | 4% |
| Series D | 3 | 4% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 48 | 66% |
| Canada | 6 | 8% |
| United Kingdom | 3 | 4% |
| China | 2 | 3% |
| Latvia | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Michael Gregory | Co-Managing Partner, Co-Founder | 1 | https://shizune.co/investors/profile/michael-gregory |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Calyxo | Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones, a common and painful condition that consumes vast amounts of healthcare resources today. Founded in 2016, Calyxo is led by executives and investors with a strong track record of commercializing paradigm-shifting solutions in thefield of urology. Our team features some of the most talented, high-achieving and brightest minds in the medical device industry who are compelled by a desire to make a difference in kidney stone care. We are proud of our collaborative, diverse, fun and dynamic culture. | $40M | Series F | Apr 14, 2026 |  |
| Immunic Therapeutics | Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $400M | Post-IPO Equity | Feb 13, 2026 |  |
| Affinia Therapeutics | Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle andcentral nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties. | $40M | Series C | Oct 07, 2025 |  |
| Jade Biosciences | Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $135M | Post-IPO Equity | Oct 07, 2025 |  |
| Jade Biosciences | Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications. | $300M | Post-IPO Equity | Apr 29, 2025 |  |
| Sirona Medical | Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care. | $42M | Series C | Nov 26, 2024 |  |
| Aktis Oncology | Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy.Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. | $175M | Series B | Sep 30, 2024 |  |
| 858 Therapeutics | 858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA. | $50M | Series B | Sep 26, 2024 |  |
| Helaina | Helaina builds better breast milk alternatives for the modern parent. It is dedicated to supporting parents with breastfeeding. It was founded in 2019 by Laura Katz and is headquartered in New York. | $45M | Series B | Sep 25, 2024 |  |
| Oruka Therapeutics | Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases. | $275M | Post-IPO Equity | Sep 03, 2024 |  |

10 of 73 investments shown.

## Co-investors
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 19 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 16 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 15 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 14 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 13 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 11 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Avidity Partners invest in?

Avidity Partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series B stage. Most of the 73 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Avidity Partners?

Public channels for Avidity Partners include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Avidity Partners?

The team at Avidity Partners includes Michael Gregory (Co-Managing Partner, Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co